Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors. Issue 8 (25th October 2020)

• Record Type: Journal Article
• Authors: Gauer, Julia S.; Riva, Nicoletta; Page, Eden M.; Philippou, Helen; Makris, Michael; Gatt, Alex; Ariëns, Robert A. S.
• Is Part Of: Research and practice in thrombosis and haemostasis. Volume 4:Issue 8(2020)
• Page Start: 1269
• Page End: 1281
• Publication Date: 2020-10-25
• Subjects: anticoagulants -- factor Xa inhibitors -- fibrin clot -- LMWH -- warfarin; Thrombosis -- Periodicals; Hemostasis -- Periodicals; 616.135005
• DOI: 10.1002/rth2.12443
• Languages: English
• ISSNs: 2475-0379

Abstract

Abstract: Background: Abnormal clot structure has been identified in patients with thrombotic disorders. Anticoagulant therapy offers clear benefits for thrombosis prevention and treatment by reducing blood clot formation and size; nevertheless, there are limited data on the effects of different anticoagulants, where clotting is initiated with different triggers, on clot structure. Objectives: Our aim was to investigate the effects of vitamin K antagonists and factor Xa inhibitors on clot structure. Methods: Clots from pooled plasma spiked with rivaroxaban, apixaban, or enoxaparin, as well as plasma from patients on warfarin, were compared to plasma without anticoagulation. The kinetic profile of polymerizing clots was obtained by turbidity, fiber density was determined by confocal microscopy, clot pore size was investigated by permeation, and fiber size was analyzed using scanning electron microscopy. Clotting agonist was either tissue factor or thrombin. Results: Following clotting with tissue factor, all anticoagulated clots had a significantly increased lag time, with the exception of enoxaparin. Rivaroxaban additionally led to significantly less dense and more permeable clots, with thicker fibers. In contrast, turbidity analysis following initiation with thrombin showed few effects of anticoagulation, with only enoxaparin leading to a prolonged lag time. Enoxaparin clots made with thrombin were less dense and more permeable. Conclusion: Our results show that anticoagulants modulate clot structure particularly when induced by tissue factor, most likely due to reduction of thrombin generation. We propose that the effects of different anticoagulants could be assessed with a global clot structure measurement such as permeation or turbidity, providing information on clot phenotype.